QZ2135
QZ2135 is a CRBN-recruiting PROTAC degrader targeting RET kinase, with a DC50 of 4.7 nM. QZ2135 induces RET degradation via the ubiquitin-proteasome system, while blocking RET phosphorylation and downstream signaling pathways, thereby inhibiting the proliferation and inducing apoptosis of cancer cells expressing wild-type or mutant RET. QZ2135 is applicable for cancer research.
(Pink: RET ligand (HY-170853); Blue: Cereblon ligand (HY-W039233); Black: linker (HY-W587352)).
For research use only. We do not sell to patients.
- Formula: C53H54N12O4
- Molecular Weight:923.07
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
RET 4.7 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
0.01 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET (WT) cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET (WT) cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
| KBALB-STK | IC50 |
0.05 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET-G810C cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET-G810C cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
| BaF3 | IC50 |
0.15 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET-G810R cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET-G810R cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
| BaF3 | DC50 |
4.7 nM
|
Induction of dose-dependent RET degradation in Ba/F3-KIF5B-RET cells measured via Western blotting normalized to actin after 6 h treatment.
Induction of dose-dependent RET degradation in Ba/F3-KIF5B-RET cells measured via Western blotting normalized to actin after 6 h treatment.
|
39731581 |
| BaF3 | DC50 |
17.2 nM
|
Induction of dose-dependent RET V804M mutant degradation in Ba/F3-KIF5B-RET-V804M cells measured via Western blotting normalized to actin after 6 h treatment.
Induction of dose-dependent RET V804M mutant degradation in Ba/F3-KIF5B-RET-V804M cells measured via Western blotting normalized to actin after 6 h treatment.
|
39731581 |
| BaF3 | DC50 |
73.8 nM
|
Induction of dose-dependent RET G810C mutant degradation in Ba/F3-KIF5B-RET-G810C cells measured via Western blotting normalized to actin after 6 h treatment.
Induction of dose-dependent RET G810C mutant degradation in Ba/F3-KIF5B-RET-G810C cells measured via Western blotting normalized to actin after 6 h treatment.
|
39731581 |
| BaF3 | DC50 |
> 300 nM
|
Induction of partial RET G810R mutant degradation in Ba/F3-KIF5B-RET-G810R cells measured via Western blotting normalized to actin after 6 h treatment.
Induction of partial RET G810R mutant degradation in Ba/F3-KIF5B-RET-G810R cells measured via Western blotting normalized to actin after 6 h treatment.
|
39731581 |
| BaF3 | IC50 |
0.04 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET-V804M cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET-V804M cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
| BaF3 | IC50 |
0.05 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET-V804L cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET-V804L cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
| BaF3 | IC50 |
0.09 μM
|
Antiproliferative activity against Ba/F3-KIF5B-RET-G810S cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against Ba/F3-KIF5B-RET-G810S cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
39731581 |
In Vitro
QZ2135 (compound 20) inhibits the kinase activities of wild-type and purified RET, with IC50 values of 5.705 nM and 5.7 nM[1].
QZ2135 (10-1000 nM; 6 h) reduces RET protein levels in Ba/F3-KIF5B-RET cells and human lung adenocarcinoma LC-2/ad cells in a dose-dependent manner[1].
QZ2135 (333.3-3000 nM; 6 h) dose-dependently reduces the RET protein level in Ba/F3-KIF5B-RETG810R cells and inhibits the level of downstream phosphorylated Shc[1].
QZ2135 (0.4-1000 nM; 0.5-24 h) induces time- and dose-dependent RET degradation in Ba/F3-KIF5B-RET cells via the ubiquitin-proteasome system, with a DC50 of 4.7 nM and a Dmax of 83%, and exerts a sustained effect even after washout[1].
QZ2135 (3.7-300 nM; 6 h) induces dose-dependent degradation of the RETV804M mutant in Ba/F3-KIF5B-RETV804M cells, with a DC50 of 17.2 nM[1].
QZ2135 (3.7-300 nM; 6 h) induces dose-dependent degradation of the RETG810C mutant in Ba/F3-KIF5B-RETG810C cells, with a DC50 of 73.8 nM[1].
QZ2135 (3.7-300 nM; 6 h) induces partial degradation of the RETG810R mutant in Ba/F3-KIF5B-RETG810R cells, with a degradation rate of approximately 43% at the concentration of 300 nM and a DC50 > 300 nM[1].
QZ2135 (11.1 nM; 6 h) induces 61.6% degradation of the RET fusion protein in human lung adenocarcinoma LC-2/ad cells[1].
QZ2135 (11.1-3000 nM; 6 h) inhibits the RET signaling pathway by suppressing the phosphorylation of RET and its downstream effector Shc in Ba/F3 cells expressing wild-type and mutant RETG810C/R[1].
QZ2135 (11.1-900 nM; 48 h) induces apoptosis in Ba/F3-KIF5B-RET cells and Ba/F3-KIF5B-RETG810C cells in a dose-dependent manner[1].
QZ2135 (72 h) potently inhibits the proliferation of Ba/F3-KIF5B-RET (WT) cells, Ba/F3-KIF5B-RET-G810C cells and Ba/F3-KIF5B-RET-G810R cells, with corresponding IC50 values of 0.01 μM, 0.05 μM and 0.15 μM[1].
QZ2135 (0.01-0.15 μM; 72 h) potently inhibits the proliferation of Ba/F3 cells expressing wild-type and mutant RET fusion proteins[1].
QZ2135 (11.1-900 nM; 48 h) induces apoptosis in Ba/F3-KIF5B-RET cells and Ba/F3-KIF5B-RETG810C cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3-KIF5B-RET cells
-
Concentration:10, 100, 1000 nM
-
Incubation Time:6 h
-
Result:Dose-dependently reduced RET protein levels in Ba/F3-KIF5B-RET cells after 6 hours of treatment.\nReduced RET protein levels in a dose-dependent manner after 6 hours of treatment.
Left levels of the CRBN neosubstrates GSPT1, CK1α, and IKZF1 unaffected.
-
Cell Line:human lung adenocarcinoma LC-2/ad cells
-
Concentration:1.2, 3.7, 11.1, 33.3, 100 nM
-
Incubation Time:6 h
-
Result:Dose-dependently reduced RET protein levels in LC-2/ad cells after 6 hours of treatment, with normalized RET/actin gray intensity decreasing as compound concentration increased.
-
Cell Line:Ba/F3-KIF5B-RET-G810R cells
-
Concentration:333.3, 1000, 3000 nM
-
Incubation Time:6 h
-
Result:Dose-dependently reduced RET protein levels in Ba/F3-KIF5B-RET-G810R cells after 6 hours of treatment.
Suppressed phosphorylated Shc levels (a downstream signaling marker) in Ba/F3-KIF5B-RET-G810R cells after 6 hours of treatment.
-
Cell Line:Ba/F3-KIF5B-RET cells, Ba/F3-KIF5B-RET-G810C cells
-
Concentration:11.1, 33.3, 100, 300 nM (Ba/F3-KIF5B-RET cells); 33.3, 100, 300, 900 nM (Ba/F3-KIF5B-RET-G810C cells)
-
Incubation Time:48 h
-
Result:Dose-dependently increased the percentage of apoptotic cells in Ba/F3-KIF5B-RET cells after 48 hours of treatment.
Dose-dependently increased the percentage of apoptotic cells in Ba/F3-KIF5B-RET-G810C cells after 48 hours of treatment.
Induced the largest proportion of apoptotic cells at the highest tested concentrations in both cell lines.
-
Cell Line:Ba/F3-KIF5B-RET cells
-
Concentration:10, 100, 1000 nM (6 h dose-response); 0.4, 1.2, 3.7, 11.1, 33.3, 100, 300, 900 nM (6 h dose-response); 30 nM (time-course); 30 nM (pretreatment + washout); 30 nM (after pretreatment with 500 nM selpercatinib, 1 μM MLN4924, 1 μM MG132, or 10 μM lenalidomide)
-
Incubation Time:6 h (dose-dependent); 0.5-12 h (30 nM time-course); 0-24 h (30 nM washout); 6 h (after 2 h pretreatment)
-
Result:Induced dose-dependent RET degradation with a DC50 of 4.7 nM and a maximal degradation of 83% after 6 h treatment.
Achieved rapid RET degradation as early as 0.5 h post-treatment with 30 nM, reaching maximal degradation by 2 h.
RET degradation persisted for 2-4 h after compound washout.
Pretreatment with Selpercatinib, MLN4924, MG132, or lenalidomide significantly attenuated RET degradation.
-
Cell Line:Ba/F3-KIF5B-RET-V804M cells
-
Concentration:3.7, 11.1, 33.3, 100, 300 nM
-
Incubation Time:6 h
-
Result:Induced dose-dependent RET degradation with a DC50 of 17.2 nM.
-
Cell Line:Ba/F3-KIF5B-RET-G810C cells
-
Concentration:3.7, 11.1, 33.3, 100, 300 nM
-
Incubation Time:6 h
-
Result:Induced dose-dependent RET degradation with a DC50 of 73.8 nM.
-
Cell Line:Ba/F3-KIF5B-RET-G810R cells
-
Concentration:3.7, 11.1, 33.3, 100, 300 nM
-
Incubation Time:6 h
-
Result:Achieved approximately 43% RET degradation at 300 nM, with a DC50 > 300 nM.
-
Cell Line:human lung adenocarcinoma LC-2/ad cells (expressing RET fusion protein)
-
Concentration:11.1 nM
-
Incubation Time:6 h
-
Result:Achieved 61.6% RET degradation.
-
Cell Line:Ba/F3-KIF5B-RET, Ba/F3-KIF5B-RET-V804M, Ba/F3-KIF5B-RET-G810C, and Ba/F3-KIF5B-RET-G810R cells
-
Concentration:11.1, 33.3, 100, 300 nM (Ba/F3-KIF5B-RET, Ba/F3-KIF5B-RET-V804M, Ba/F3-KIF5B-RET-G810C); 333.3, 1000, 3000 nM (Ba/F3-KIF5B-RET-G810R)
-
Incubation Time:6 h
-
Result:Effectively inhibited phosphorylation of RET and Shc in Ba/F3-KIF5B-RET and Ba/F3-KIF5B-RET-V804M cells.
Nearly abolished phosphorylation of RET-G810C and Shc at 300 nM, while selpercatinib showed no suppression at 100 and 300 nM.
Reduced phosphorylation of RET-G810R and Shc at concentrations from 333.3-3000 nM.
-
Cell Line:Ba/F3-KIF5B-RET and Ba/F3-KIF5B-RET-G810C cells
-
Concentration:11.1, 33.3, 100, 300 nM (Ba/F3-KIF5B-RET); 33.3, 100, 300, 900 nM (Ba/F3-KIF5B-RET-G810C)
-
Incubation Time:48 h
-
Result:Induced dose-dependent apoptosis, achieving apoptosis rates of 48.3% at 300 nM in Ba/F3-KIF5B-RET cells and 31.8% at 300 nM in Ba/F3-KIF5B-RET-G810C cells.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6 per group, Ba/F3-KIF5B-RET-G810C cell subcutaneous xenograft, tumors grown to ~150 mm3 before treatment)[1]
-
Dosage:10 mg/kg (14-day TGI, 3-day RET degradation); 30 mg/kg (14-day TGI, 14-day tumor weight reduction, 3-day RET degradation)
-
Administration:i.p.; once daily for 14 days; i.p.; once daily for 3 days
-
Result:Achieved 31.6% tumor growth inhibition (TGI) at 10 mg/kg.
Degraded RET protein in tumors by 47.0% at 10 mg/kg.
Achieved 49.2% TGI at 30 mg/kg.
Reduced tumor weight by 34.4% at 30 mg/kg.
Degraded RET protein in tumors by 55.3% at 30 mg/kg.
Caused no significant body weight changes compared to vehicle controls.
Chemical Information
-
Molecular Weight 923.07
-
Formula C53H54N12O4
-
SMILES
N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(C7=CN(C8CCN(CCCCCC#CC9=CC=CC%10=C9CN(C(CC%11)C(NC%11=O)=O)C%10=O)CC8)N=C7)=CN2N=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)